Australasian biotechnology firm Living Cell Technologies (LCT) has completed patient enrollment in a Phase I/IIa clinical trial of the regenerative cell therapy NTCELL for Parkinson’s disease.
NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.
The open-label trial will evaluate the safety and clinical effects of NTCELL in patients who can no longer respond to the existing therapy.
The capsule is directed by Parkinson's disease clinician and researcher Dr Barry Snow who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board.
LCT chief executive Dr Ken Taylor said: " I congratulate the clinical team at Auckland Hospital for the coordination and interaction with all required regulatory and ethical authorities required to successfully recruit all patients for this innovative clinical study.
"Now we look forward to the clinical study outcome in 2015. We remain excited about the potential for NTCELL to be the first disease modifying treatment for patients who are failing the current conventional treatment for Parkinson's disease."
The company said that NTCELL also has the potential to be used in a number of other central nervous system (CNS) indications such as Huntington's, Alzheimer's and motor neurone diseases.
No comments:
Post a Comment